Evidence map›Paper›PMID 40012597›Full record

ArticleBrain circulation

Association of baseline plasma fibrinogen levels with cognitive and affective status at 30 and 90 days in individuals with ischemic stroke: A prospective study from Nigeria.

Adekola B Ademoyegun, Taofeek O Awotidebe, Marufat O Odetunde, Samuel O Inaolaji, Serifat O Bakare, Funmilola W Azeez, Olanrewaju Olayemi

Abstract read
In one paragraph

Article in Brain circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adekola B AdemoyegunDepartment of Physiotherapy, Osun State University Teaching Hospital, Osogbo, Nigeria.
Taofeek O AwotidebeDepartment of Medical Rehabilitation, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Marufat O OdetundeDepartment of Medical Rehabilitation, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Samuel O InaolajiDepartment of Physiotherapy, Osun State University Teaching Hospital, Osogbo, Nigeria.
Serifat O BakareDepartment of Family Medicine, Accident and Emergency Unit, Osun State University Teaching Hospital, Osogbo, Nigeria.
Funmilola W AzeezDepartment of Family Medicine, Accident and Emergency Unit, Osun State University Teaching Hospital, Osogbo, Nigeria.
Olanrewaju OlayemiDepartment of Internal Medicine, Osun State University Teaching Hospital, Osogbo, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe influence of fibrinogen as a risk factor in developing poststroke neuropsychological and cognitive problems is underreported. This study aimed to evaluate the relationship between baseline fibrinogen levels and depression, anxiety, and cognition 30- and 90-day after stroke.

methodsThis prospective study involved 48 patients with first-ever mild-to-moderate ischemic stroke, whose plasma fibrinogen levels were assessed within 24 h of stroke onset. Clinical depression, anxiety, and cognitive impairment were evaluated by the Hospital Anxiety and Depression Scale and Montreal Cognitive Assessment at 30- and 90-day after stroke.

resultsAfter adjusting for important covariates, the multiple linear regression models showed that baseline plasma fibrinogen was associated with the symptoms of depression, anxiety, and cognitive decline at both 30- and 90-day follow-up (

conclusionsHigh levels of baseline plasma fibrinogen are associated with the onset and severity of symptoms of depression, anxiety, and cognitive decline at 30 and 90 days after stroke. This study shows that fibrinogen may be a viable target for monitoring and intervention in the management of poststroke neuropsychological and cognitive disorders. Future clinical trials are needed to clarify whether defibrinogenation will prevent or reduce the rate and severity of symptoms of depression, anxiety, and cognitive decline among patients with ischemic stroke.

trial registrationPan African Clinical Trial Registry (registration number: PACTR202406755848901).

Indexed as

Anxietycognitive declinedepressionfibrinogenstroke

Identifiers

PMID40012597
PMCPMC11850936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.